Sign In
Buy CKPT
$4.26
+0 (+0%)
At Close: Aug 29, 2025
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success
04:50pm, Tuesday, 27'th Aug 2024
Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual mechani
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
01:00pm, Friday, 16'th Aug 2024
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
08:30am, Monday, 12'th Aug 2024
WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financi
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that th
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
08:00am, Monday, 15'th Jul 2024
YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore t
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Tuesday, 02'nd Jul 2024
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has
Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab
07:00am, Tuesday, 02'nd Jul 2024
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
07:30am, Monday, 24'th Jun 2024
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (N
CKPT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
11:00am, Tuesday, 04'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Ch
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
12:21pm, Monday, 03'rd Jun 2024
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint” or t
CKPT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
12:15pm, Monday, 03'rd Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Ch
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
